Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 855.

https://doi.org/10.1182/blood-2023-177588

Published: 2023

Journal Articles

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2023-174213

Published: 2023

Journal Articles

Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Adam J. Olszewski, Abraham Avigdor, Sunil Babu, Itai Levi, Herbert Eradat, Uri Abadi, Houston Holmes, Matthew McKinney, Dariusz Woszczyk, Krzysztof Giannopoulos, Wojciech Jurczak, Diana Dunshee, Annie Yang, Mingzhu Zhou, Naseer Qayum, Gila Sellam, Netanel A. Horowitz

Blood (2022) 140 (Supplement 1): 1778–1780.

https://doi.org/10.1182/blood-2022-157768

Published: 2022

Journal Articles

Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Martin Hutchings, Anna Sureda, María José Terol, Francesc Bosch Albareda, Paolo Corradini, Thomas Stauffer Larsen, Antonio Rueda Dominguez, Anesh Panchal, Alessia Bottos, David Carlile, Yanjie Wang, Audrey Filézac De L'Étang, Maneesh Tandon, Gila Sellam, Giuseppe Gritti

Blood (2021) 138 (Supplement 1): 525.

https://doi.org/10.1182/blood-2021-148359

Published: 2021

Journal Articles

Unmet Medical Need Among Elderly Patients with Previously Untreated DLBCL Characterized Using Real-World Data in the United States

Ashwini Shewade, Adam J Olszewski, MD, Nelson Pace, Andy Surinach, MPH, Gila Sellam, Lars Mueller, Carol O'Hear

Blood (2020) 136 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2020-136271

Published: 2020

Journal Articles

Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Adam J Olszewski, MD, Abraham Avigdor, MD, Sunil Babu, Itai Levi, MD, Uri Abadi, Houston Holmes, Matthew McKinney, Ron McCord, Yuying Xie, Cindy Chen, Kati Sarouei, Naseer Qayum, Carol O'Hear, Gila Sellam, Herbert Eradat

Blood (2020) 136 (Supplement 1): 43–45.

https://doi.org/10.1182/blood-2020-136255

Published: 2020

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, MD, Bruce D. Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, MD, Uwe H Hahn, MD, Eliza A Hawkes, Cyrus Khan, MD, Izidore S. Lossos, MD, Gerardo Musuraca, MD PhD, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, MBBS,FRCPA,FRACP, Aparna Raval, PhD, Mahesh R. Shivhare, PhD, Tina G Nielsen, MD PhD, Gila Sellam, PhD, Jeff P. Sharman, MD

Blood (2019) 134 (Supplement_1): 2874.

https://doi.org/10.1182/blood-2019-123368

Published: 2019

Journal Articles

Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Lale Kostakoglu, MD MPH, Maurizio Martelli, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Andrea Knapp, PhD, Federico Mattiello, PhD, Tina G Nielsen, MD PhD, Deniz Sahin, BSc, Gila Sellam, PhD, Carol Ward, MSc, Anas Younes, MD

Blood (2019) 134 (Supplement_1): 489.

https://doi.org/10.1182/blood-2019-123626

Published: 2019

Journal Articles

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Laurie H Sehn, MD, Maurizio Martelli, MD, Marek Trněný, MD, Wenxin Liu, PhD, Christopher R Bolen, PhD, Andrea Knapp, PhD, Deniz Sahin, BSc, Gila Sellam, PhD, Umberto Vitolo

Blood (2019) 134 (Supplement_1): 4088.

https://doi.org/10.1182/blood-2019-123433

Published: 2019

Journal Articles

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Magdalena Klanova, Laurie H. Sehn, Isabelle Bence-Bruckler, Federica Cavallo, Jie Jin, Maurizio Martelli, Douglas Stewart, Umberto Vitolo, Francesco Zaja, Qingyuan Zhang, Federico Mattiello, Gila Sellam, Elizabeth A. Punnoose, Edith Szafer-Glusman, Christopher R. Bolen, Mikkel Z. Oestergaard, Guenter R. Fingerle-Rowson, Tina Nielsen, Marek Trneny

Blood (2019) 133 (9): 919–926.

https://doi.org/10.1182/blood-2018-07-862862

Published: 2019

Includes: Supplemental data

Journal Articles

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Shigeru Kusumoto, Luca Arcaini, Xiaonan Hong, Jie Jin, Won Seog Kim, Yok Lam Kwong, Marion G. Peters, Yasuhito Tanaka, Andrew D. Zelenetz, Hiroshi Kuriki, Günter Fingerle-Rowson, Tina Nielsen, Eisuke Ueda, Hanna Piper-Lepoutre, Gila Sellam, Kensei Tobinai

Blood (2019) 133 (2): 137–146.

https://doi.org/10.1182/blood-2018-04-848044

Published: 2019

Includes: Supplemental data

Journal Articles

No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study

Laurie H Sehn, MDMPH, Angela Giovanna Congiu, Dominic J. Culligan, Mercedes Gironella, Dok Hyun Yoon, Michinori Ogura, Andras Rosta, Jun Zhu, Aino Launonen, Tina Nielsen, Gila Sellam, Marek Trněný, Umberto Vitolo, Maurizio Martelli

Blood (2018) 132 (Supplement 1): 783.

https://doi.org/10.1182/blood-2018-99-116845

Published: 2018

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, Bruce Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, Uwe Hahn, Eliza Hawkes, Cyrus Khan, Izidore S. Lossos, MD, Gerardo Musuraka, Monica Tani, Umberto Vitolo, Sam Yuen, Mikkel Z Oestergaard, Surya Chitra, Michael Wenger, Tina Nielsen, Gila Sellam, Jeff Sharman, MD

Blood (2018) 132 (Supplement 1): 2969.

https://doi.org/10.1182/blood-2018-99-116678

Published: 2018

Journal Articles

Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials

Sarah C. Rutherford, Michael Herold, Wolfgang Hiddemann, Lale Kostakoglu, Robert Marcus, Maurizio Martelli, Laurie H Sehn, MDMPH, Marek Trněný, Judith Trotman, Umberto Vitolo, Tina Nielsen, Federico Mattiello, Deniz Sahin, Gila Sellam, Peter Martin, FRCPC, MD MS

Blood (2018) 132 (Supplement 1): 1605.

https://doi.org/10.1182/blood-2018-99-114913

Published: 2018

Journal Articles

Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study

Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, MDMPH, David Belada, Angelo-Michele Carella, Neil Chua, Eva Gonzalez-Barca, Xiaonan Hong, Antonio Pinto, MD, Yuankai Shi, Yoichi Tatsumi, Günter Fingerle-Rowson, Andrea Knapp, Federico Mattiello, Tina Nielsen, Gila Sellam, Denis Sahin, Umberto Vitolo, MD, Marek Trněný, MD PhD

Blood (2017) 130 (Supplement 1): 824.

https://doi.org/10.1182/blood.V130.Suppl_1.824.824

Published: 2017

Journal Articles

Managing the Risk of Hepatitis B Virus Reactivation in Patients with B-Cell Lymphomas Treated with Obinutuzumab or Rituximab Immunochemotherapy

Shigeru Kusumoto, MD, Luca Arcaini, MD, Xiaonan Hong, Jie Jin, Won Seog Kim, MD, Ph. D., Yok Lam Kwong, Marion Peters, Yasuhito Tanaka, Andrew D. Zelenetz, MD PhD, Hiroshi Kuriki, Günter Fingerle-Rowson, Tina Nielsen, Eisuke Ueda, Hanna Piper-Lepoutre, Gila Sellam, Kensei Tobinai, MD PhD

Blood (2017) 130 (Supplement 1): 2823.

https://doi.org/10.1182/blood.V130.Suppl_1.2823.2823

Published: 2017

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis

Anas Younes, MD, Burke M. John, Catherine S Diefenbach, Silvia Ferrari, Cyrus Kahn, Jeffrey P. Sharman, MD, Monica Tani, Chaitra S. Ujjani, MD, Umberto Vitolo, MD, Sam Yuen, Paul Woodard, Kirsten Mundt, Günter Fingerle-Rowson, Surya Chitra, Gila Sellam, Rodica Morariu-Zamfir, Michael Gilbertson

Blood (2017) 130 (Supplement 1): 481.

https://doi.org/10.1182/blood.V130.Suppl_1.481.481

Published: 2017

NARROW

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Unmet Medical Need Among Elderly Patients with Previously Untreated DLBCL Characterized Using Real-World Data in the United States

Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials

Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study

Managing the Risk of Hepatitis B Virus Reactivation in Patients with B-Cell Lymphomas Treated with Obinutuzumab or Rituximab Immunochemotherapy

Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only